News Updates

Zydus receives final approval from USFDA for Vigabatrin Tablets

Zydus Wellness registers net sales of Rs.3,849 mn and net profit of Rs.233 mn in Q3

Zydus supplies the first consignment of its COVID-19 vaccine ZyCoV-D

Zydus posts consolidated revenues of Rs. 3655 crores in Q3

Zydus gets 180 days shared exclusivity for Roflumilast Tablets

Cadila Healthcare Limited is now Zydus Lifesciences Limited

Zydus gets final approval for Dapagliflozin Tablets

Zydus to launch Oxemia (Desidustat) a breakthrough treatment for Anemia in patients suffering from Chronic Kidney Disease (CKD)

Sentynl Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) and BridgeBio Pharma Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRYTM (Fosdenopterin)

Zydus receives final approval from USFDA for Nitroglycerin Sublingual Tablets

Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets

Fortress Biotech and Cyprium Therapeutics alongwith Zydus’ Sentynl Therapeutics Announce CUTX-101, Copper Histidinate Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting

Zydus receives Prior Approval Supplement (PAS) approval from USFDA for Mycophenolate Mofetil for Injection USP

The Lancet publishes Phase III data of ZyCoV-D

Zydus to supply Sagent’s Caffeine Citrate Oral Solution from Jarod, post USFDA’s PAS Approval

Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection

Zydus announces publication of “DREAM-ND” and “DREAM-D” Phase 3 trials of Desidustat in “American Journal of Nephrology”

ZyCoV-D as a two-dose vaccine receives EUA from DCGI

Zydus receives final approval from USFDA for Bortezomib for Injection

Zydus Lifesciences receives final approval from USFDA for Bortezomib for Injection

Zydus Lifesciences receives tentative approval from USFDA for Selexipag tablets

Zydus receives tentative approval from USFDA for Selexipag Tablets

Zydus announces the launch of Bemdac for the first time in India to treat uncontrolled LDL-Cholesterol

Zydus announces the launch of Bemdac® for the first time in India to treat uncontrolled LDL-Cholesterol

Zydus Lifesciences Limited Reports Financial Performance for Q4 FY22 and Full Year FY22

Zydus Lifesciences Limited Reports Financial Performance for Q4 FY22 and Full Year FY22

Zydus receives final approval to market Pemetrexed for Injection 2

Press Release Zydus receives EIR from USFDA for its injectables manufacturing facility at Jarod

Press Release Zydus Lifesciences receives final approval from USFDA for Famotidine Tablets

Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel

Zydus has launched Sitaglyn® and Siglyn® (Sitagliptin), for the management of Type 2 diabetes

Zydus receives final approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets

Zydus receives final approval from the USFDA for Norepinephrine Bitartrate Injection

Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets

Zydus Receives Final Approval From The USFDA For Empagliflozin Tablets

Zydus Receives Final Approval From The USFDA For Ivermectin Cream

Zydus Lifesciences Limited Financial Performance for Q1 FY23

Zydus receives final approval from the USFDA for Prochlorperazine Maleate Tablets

Zydus announces Phase IV DREAM-CKD trial to generate Real World Evidence of Desidustat in patients with Chronic Kidney Disease induced anemia

Zydus receives two final approvals from the USFDA

Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS)

Zydus in-licenses a critical drug for CKD patients from Pharmacosmos of Denmark

Zydus receives final approval and 180 days shared exclusivity from the USFDA for Cariprazine Capsules

Zydus receives final approval from the USFDA for Lenalidomide Capsules 5 mg, 10 mg, 15 mg and 25 mg

Zydus develops new treatment for patients suffering from Chronic Kidney Disease (CKD), submits first New Drug Application (NDA) to DCGI

Zydus Cadila gets 180-day exclusivity for Nelarabine injection, announces final approval from USFDA

Zydus Cadila receives final approval from USFDA for Glycopyrrolate Injection

Cadila Healthcare Ltd., to supply 1 crore doses of ZyCoV-D, the world’s first Plasmid DNA vaccine to the Government of India